Drug intelligence / Profile preview

SHR-2906

Development stage: Phase 1
Lead developer: Shanghai Hengrui Pharmaceutical Co., Ltd.
Modality: Small Molecules
Administration: Intravenous Injection

Overview

SHR-2906 is a small molecule drug in clinical development for the treatment of obesity and overweight conditions[3][6]. Developed by Jiangsu Hengrui Pharmaceuticals (with initial development by Beijing Suncadia Pharmaceuticals), the drug is a therapeutic biological product designed to provide synergistic effects in weight management[9]. The drug is currently under investigation in a Phase I clinical trial that evaluates both single-dose administration in healthy subjects and multiple-dose administration in obese patients[3][13].

Other names: SHR-2906 InjectionSHR2906 InjectionSHR 2906 Injection

Beyond the preview

Go deeper on SHR-2906.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-2906.

Explore the full profile